Please visit answersincme.com/KDX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the use of neoadjuvant immunotherapies in the treatment of surgically resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the rationale for using neoadjuvant immunotherapies for patients with surgically resectable CSCC; Review the latest evidence on the efficacy and safety of emerging neoadjuvant immunotherapies for patients with surgically resectable CSCC; and Outline clinical strategies to optimize the therapeutic management of surgically resectable CSCC for patients who would be appropriate candidates for neoadjuvant immunotherapies.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related